



TIBARAY
CURING CANCER IN A *FLASH*™

**400X Faster
Effective Tumor Killing
Far Less Collateral Damage**

Compared To Current Cancer Treatments



TIBARAY, INC.

**Patented Radiotherapy Technology
Designed to Help Cure Cancer in a
FLASH™**

tibaray.com Fremont, CA

Highlights

- 1 Robust IP portfolio with 20+ issued and pending patents on next-generation radiotherapy technology.
- 2 Partnership with an innovative radiotherapy technology provider to integrate core technology.
- 3 \$9 billion global radiotherapy market with adjacent multi-billion dollar applications.

- 4 24,000 sq ft fully integrated Silicon Valley facility for prototyping, testing, and production.
- 5 Led by a CEO who built a NASDAQ-listed company to a \$2B market cap.
- 6 Team of world-class physicists, engineers, and clinical advisors.

Featured Investor



Tuoc Luong
Syndicate Lead

Follow

Invested \$605,000

<https://www.linkedin.com/in/tuocluong/>

"I have 3 investment thesis: 1) Innovative Technology and a moat that is difficult for competitors to cross 2) Does the technology and product provide a benefit for society. Tibaray has both of these qualities. 3) Does the company have the right leader and team to succeed. I think the CEO Thinkh Tran has the experience of taking a company from startup to IPO and further (he has shown this in the past). From a technology perspective there are some big name professors from Stanford who are the leading experts in their fields. So Tibaray has the team, the technology moat and what it does benefit society. Love it!"

Team



Thinkh Tran CEO & Director

Mr. Tran is a Stanford graduate, Founder & CEO of Vita Imaging and Founder & former CEO of Sigma Designs, which he grew from startup to a NASDAQ-listed company with a ~\$2B market cap. He brings 40+ years of leadership, capital-raising, and M&A experience.

tibaray.com



Sami Tantawi CTO, Co-Founder, Director

Professor Sami Tantawi is an ASU Physics professor, former Stanford professor, and former SLAC chief scientist. He led world-class RF



accelerator research, won the U.S. Particle Accelerator School achievement award, and is an APS Fellow.

search.asu.edu



Bill Loo, MD, PhD Chief Medical Advisor, Co-Founder, Director

Billy W. Loo Jr., MD PhD is a Stanford Professor and Director of Thoracic Radiation Oncology, a global leader in lung cancer radiotherapy, FLASH therapy, and proton therapy, and co-inventor of PHASER, a breakthrough ultra-precise cancer therapy.

med.stanford.edu



Peter Maxim Co-Founder, Director

Peter Maxim is Professor and Vice-Chair of Medical Physics at UC Irvine and Co-founder of TibaRay. A leader in SABR and ultra-fast FLASH radiation, he holds multiple patents, major AAPM awards, and is advancing sub-second curative radiotherapy worldwide.

faculty.uci.edu



Rebecca Fahrig Co-Founder

Rebecca Fahrig, PhD, is a pioneer in x-ray imaging and cone-beam CT. Former Stanford Radiology faculty, now VP of Innovations at Siemens Healthcare, leading 50 scientists developing next-gen image guidance systems.



Revolutionizing Cancer Treatment with FLASH


TibaRay is building an ultra-fast, ultra-precise radiotherapy platform to dramatically improve cancer outcomes while reducing side effects, cost, and treatment time.

We are not just improving cancer therapy. We are redefining what is curable.



Cancer is The #1 Killer Worldwide

2 in 5 people will develop cancer



1 in 5 will die of it.

The Solution

TibaRay enables FLASH—delivering treatment in a fraction of a second instead of minutes, over 400X faster than today’s state-of-the-art technology. Recent research shows that this can greatly reduce normal tissue damage, allowing for more curative treatments. In addition, twice as many patients can be treated at reduced costs.

400X Faster Than Current Treatments

40% Reduction in Damage to Healthy Tissue



Current fastest treatment in the world is
over 3 minutes




TibaRay PHASER™ treats in
approximately 0.3 seconds

Today's Radiation Therapy Is Too Slow

10-12 million patients worldwide should be eligible for radiotherapy each year, but only about 5-6 million actually receive it because they lack access.

Tumor Moves




Patient and tumor movement during treatment forces radiation to cover a larger area, damaging healthy tissue.

Collateral Damage



Radiation injuries include scarring, inflammation, loss of function, etc.

Bottleneck



Treatments can be costly and inaccessible. Limited availability means people are going untreated everyday.

FLASH radiobiology is a new scientific discovery showing that ultra-rapid radiation can **spare healthy tissue** without compromising tumor kill. TibaRay's advances in accelerator physics, RF systems, and beam control now make conformal FLASH **clinically feasible** for the first time.

Our Proprietary PHASER Platform

(Pluridirectional High-energy Agile Scanning Electronic Radiotherapy)



“Freezes” tumor motion

Reduces collateral damage

Treatment **only** to the tumor

Higher throughput & lower cost

The Tech Powering PHASER

Over the past decade TibaRay has been developing revolutionary linear accelerator and RF component technologies **invented at Stanford University**. More than **\$27 million** has been invested, including more than **\$14 million** in

non-dilutive highly competitive federal grants. These technologies are commercial today and will power PHASER in the near future.

TibaRay Galactica™ 8 MV Linear Accelerator


A new accelerator design in over 60 years. Based on exclusively licensed breakthroughs from Stanford/SLAC & ASU, and TibaRay advances.

2X better power efficiency

3X higher dose rate

Integrated RF beam monitor

Variable energy and dose rate



Our Galactica linac has been designed into the Leo Cancer Care treatment system, marking the first TibaRay Inside™ commercial partnership integrating Galactica into Leo's complete treatment platform.

Major Radiotherapy Partner Leo Cancer Care

Galactica's industry-leading dose rate allows:

- Accurate treatment - faster treatment, greater precision, less collateral tissue damage
- Clinical efficiency - higher throughput and greater patient volumes
- Unmatched industry performance - market leading MLC speed, most accurate image-guided radiotherapy




Market Opportunity

Market Opportunity

We are initially focusing on cancer care and treating patients with tumors anywhere in the body.

The cancer therapy market is **\$300 billion overall** with radiotherapy being **\$9 billion** (currently with 6-8% CAGR).



7,742,322

10-12M patients worldwide require radiotherapy each year, but only about 5-6M actually receive it because of lack of access.

Radiotherapy is used in over **60%** of U.S. cancer treatments.

In addition, there's **\$20 billion** in opportunities for applications in other major illnesses:

- Cardiac arrhythmias (e.g., ventricular tachycardia*, atrial fibrillation)
- Pulmonary emphysema*
- Functional neurologic conditions
- Arthritis & inflammatory conditions
- Others (potentially Alzheimer's, etc.)...

*First human clinical trials of focused radiotherapy performed by Dr. Bill Loo



8,359,255

10-12M patients worldwide require radiotherapy each year, but only about 5-6M actually receive it because of lack of access.

Radiotherapy is used in over **60%** of U.S. cancer treatments.



In addition, there's \$20 billion in opportunities for applications in other major illnesses:

- Cardiac arrhythmias (e.g., ventricular tachycardia*, atrial fibrillation)
- Pulmonary emphysema*
- Functional neurologic conditions
- Arthritis & inflammatory conditions
- Others (potentially Alzheimer's, etc.)...


*First human clinical trials of focused radiotherapy performed by Dr. Bill Loo

Competitive Advantage

Our World-Class Expertise is our Competitive Advantage, Augmented by our Exclusive IP

Key Exclusive Licenses from Stanford University:


- Multiple accelerators (US, EP)
- Overall PHASER concept (US, CN, EP)
- Linear accelerator (US)
- Klystrinos (US)
- RF power distribution (US)
- Compact isolator (US)
- Beam collimator (US, EP)



TibaRay IP:

- Accelerator design
- Beam Monitor
- Advanced compact isolator

24,000 sq ft fully integrated Silicon Valley facility



Fully integrated facility with:

- Large radiation-shielded vault (radiation safety approved)
- Advanced production capabilities with CNCs and hydrogen brazing bonding furnace
- Accelerator production QMS compliant with ISO 13485

Recent Features

PRESS RELEASE

LEO CANCER CARE PLANS TO INTEGRATE TIBARAY LINACS INTO FUTURE GRACE PHOTON THERAPY PLATFORM

OCTOBER 3, 2025

Leo Cancer Care announced that it has placed orders for TibaRay's advanced linear accelerators (linacs). TibaRay's accelerators are designed to deliver higher dose rates than conventional systems, opening the possibility for new treatment paradigms such as FLASH radiotherapy, while also offering a more compact footprint that aligns well with Leo Cancer Care's upright treatment approach.

Malaysia's IHH Healthcare makes oncology push with investment in US firm TibaRay

By Reuters

January 28, 2026 11:59 PM PST · Updated January 28, 2026





“The investment gives IHH exposure to TibaRay's radiation therapy technology.”



Here's
how **you**
can make
a difference

Join our mission to save millions of lives by transforming cancer radiotherapy—making treatment more effective, more accessible, and safer for patients worldwide.